Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
10 déc. 2020 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that the...
Entera Bio Appoints Spiros Jamas as Chief Executive Officer
30 nov. 2020 16h05 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its...
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
19 nov. 2020 06h30 HE
|
Entera Bio Ltd.
‒ Completed Enrollment in Phase 2 Clinical Trial of EB613, Positioned as the First Potential Oral Bone Building Product to Treat Osteoporosis ‒‒ Positive Interim 6-Month Bone Mineral Density (BMD)...
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
13 nov. 2020 07h30 HE
|
Entera Bio Ltd.
BOSTON JERUSALEM, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business and...
Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis
09 nov. 2020 08h30 HE
|
Entera Bio Ltd.
‒ Company Expects to Report Interim 3 Month Biomarker Data for All Enrolled Patients in Q1:21 with Final Bone Mineral Density, or BMD, Data Expected in Q2:21 ‒ ‒ Results Expected Are Expected to...
Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference
02 nov. 2020 16h05 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its...
Entera Bio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
10 sept. 2020 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its...
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
20 août 2020 06h30 HE
|
Entera Bio Ltd.
‒ 6-Month Interim Data Indicate EB 613 Has Meaningful and Positive Impact on Lumbar Spine Bone Mineral Density (BMD) in a Dose Dependent Manner –‒ Company Expects to Complete Patient Enrollment in...
Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020
17 août 2020 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced it will report business...
Entera Bio Announces Management Changes
10 août 2020 08h30 HE
|
Entera Bio Ltd.
BOSTON and JERUSALEM, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today that its Board of...